Clinical trials: Other Endocrine/Nutritional/Metabolic Disorder
Type 2 Diabetes Mellitus
Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients
The aim of this study is to evaluate the effectiveness and safety of the triple combination therapy of Zemidapa Tab. and Metformin in patients with type 2 diabete mellitus
- Trial name
- NCT06495281
- Where
- South Korea
- Volunteers
- 2,044 people
- Sponsor
- LG Chem
Prostate Cancer, Urologic Cancer
The Man Van Project
National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the aim of enabling male patients' easy access to care…
- Conditions
- Prostate Cancer, Urologic Cancer, Urologic Diseases, Bladder Cancer
- Trial name
- MV (NCT06357416)
- Testing
- MV-POCT Sub-study, Main Man Van Group Sub-study (MV-Eco), MV-QualQ Sub-study
- Where
- United Kingdom
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Schizophrenia, Schizoaffective Disorder
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
Primary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
- Trial name
- NCT00690235
- Testing
- Pramlintide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus
Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment
The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.
- Trial name
- NCT00046462
- Testing
- Lantus (insulin glargine [rDNA origin] injection), Metformin, Glyburide
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Sanofi
Diabetes Mellitus
Comparative Measurement of Microcirculation and Other Parameters With the Vital USA VitalDetect™ in Patients With Diabetes Mellitus Type 1 and Type 2 Versus Healthy Participants
The purpose of this clinical study is to optimize the measurement algorithm of the Vital USA VitalDetectTM in measuring the microcirculating blood flow.
- Trial name
- NCT06063759
- Testing
- VitalDetect
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sciema UG
Type 2 Diabetes Mellitus, Schizophrenia
Lifestyle Intervention for Diabetes and Weight Management in Psychosis
The rate of type-2 diabetes mellitus (T2DM) is at least 2-3 times higher in persons with psychotic illnesses than in the general population.
- Conditions
- Type 2 Diabetes Mellitus, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- Healthy_LIFE (NCT01828931)
- Testing
- Lifestyle Intervention, Usual Care
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Type 2 Diabetes Mellitus
Janssen - Glucose Regulation/Risp/Olanz
Abnormalities in peripheral glucose regulation and type 2 diabetes can occur more commonly in individuals with schizophrenia than in healthy subjects or in other psychiatric conditions.
- Trial name
- NCT00205738
- Testing
- Risperidone, Olanzapine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Schizophrenia, Schizoaffective Disorder
Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone
Having a diagnosis of schizophrenia or bipolar disorder and being treated with certain of the newer antipsychotics are risk factors for development of diabetes.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00538642
- Testing
- ziprasidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2
Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia
The purpose of this study is to investigate the glycaemic control and other clinical parameters in adult patients previously treated with basal insulin (with or without OADs) and switched to IDegLira in real-world clinical…
- Trial name
- SPIRIT (NCT05324462)
- Testing
- IDegLira
- Where
- 6 sites in Colombia
- Volunteers
- 175 people
- Sponsor
- Novo Nordisk A/S
Schizophrenia, Type 2 Diabetes Mellitus
Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
This proposal aims to use well-validated methodologies such as dual energy x-ray absorptiometry (DEXA), frequently sampled oral glucose tolerance tests (fsOGTTs), and hyperinsulinemic euglycemic clamps to characterize the…
- Trial name
- BMS (NCT00205660)
- Testing
- Stayers, Switchers
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
NAFLD, NASH
The European NAFLD Registry
The European NAFLD Registry is a prospectively recruited, observational study supporting the study of the clinical phenotype, natural history, disease outcomes and pathophysiology of Non-Alcoholic Fatty Liver Disease and…
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
- Trial name
- NCT04442334
- Where
- 37 sites in Belgium, Finland and 10 more
- Volunteers
- 10,000 people
- Sponsor
- Newcastle University
Obesity, Microalbuminuria
Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors
Primary objective: To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period.
- Conditions
- Obesity, Microalbuminuria, Diabetes Mellitus, Type 2, Dyslipidemia
- Trial name
- RIALTO (NCT00458081)
- Testing
- Rimonabant
- Where
- Spain
- Volunteers
- 174 people
- Sponsor
- Sanofi
Diabetes, Pre-diabetes
Northern Manhattan Study of Metabolism and Mind
Pre-diabetes, type 2 diabetes, and their related conditions, adiposity and insulin resistance, are more prevalent in minorities Northern Manhattan compared to the general population of the United States.
- Conditions
- Diabetes, Pre-diabetes, Cognition - Other, Depressive Symptoms
- Trial name
- NOMEM (NCT02470260)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Schizophrenia, Schizoaffective Disorder
Glucose and Lipid Metabolism on Antipsychotic Medication
This project aims to a) evaluate the effects of selected antipsychotic medications on insulin action in skeletal muscle (glucose disposal), liver (glucose production) and adipose tissue (whole-body lipolysis), b) evaluate the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
- Trial name
- Glulipid (NCT00515723)
- Testing
- risperidone, olanzapine, quetiapine
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Endothelial Dysfunction, Diabetes Mellitus, Type 1
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
The aim of study is impact of additional treatment with new antidiabetic drugs (semaglutide or empagliflozine) compared to control group in T1DM patients - impact on endothelial function measured by FMD and FPF, arterial…
- Conditions
- Endothelial Dysfunction, Diabetes Mellitus, Type 1, Biomarkers, Endothelial Progenitor Cells
- Trial name
- ENDIS (NCT05857085)
- Testing
- Semaglutide Pen Injector [Ozempic], Empagliflozin 10 MG
- Where
- Slovenia
- Volunteers
- 90 people
- Sponsor
- General and Teaching Hospital Celje
Diabetes, Cardiovascular Disease
A Complex Contraception Registry
The investigators will conduct a prospective observational cohort study to investigate factors that influence contraceptive method utilization among women with medical conditions.
- Conditions
- Diabetes, Cardiovascular Disease, Epilepsy, Migraine
- Trial name
- NCT02219269
- Where
- 5 sites in United States
- Volunteers
- 97 people
- Sponsor
- University of California, San Diego
Diabetes Mellitus, Type 2
This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations
The primary objective of this exploratory meta-analysis is to evaluate the frequencies, incidence rates, and hazard ratios of lower-limb amputation (LLA) events (primary outcome) and of adverse events related to amputation…
- Trial name
- NCT04937816
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 16,746 people
- Sponsor
- Boehringer Ingelheim
Adverse Pregnancy Outcomes, Cardiovascular Diseases
A Randomized Trial to Reduce Blood Pressure at One Year Postpartum After Preeclampsia
GESTA-COR is a prospective, randomized clinical trial designed to evaluate whether an early, personalized cardiovascular prevention strategy can achieve a clinically meaningful 6 mmHg reduction in systolic blood pressure at one…
- Trial name
- GESTA-COR (NCT06798649)
- Testing
- The intervention in the GESTACOR study involves providing detailed feedback from vascular imaging to women who have experienced adverse pregnancy outcomes (APOs).
- Volunteers
- 150 people
- Sponsor
- Maternal-Infantil Vall d´Hebron Hospital
Type 2 Diabetes
Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes Mellitus
Aim: The purpose of this study is to compare the effects of glimepiride(G) and metformin(M) on vascular reactivity, haemostatic factors and glucose and lipid profile in patients with type 2 diabetes.
- Trial name
- NCT01509001
- Testing
- Metformin, Glimepiride
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo